ATA Index: A novel score for predicting fibrosis stage in chronic viral hepatitis.
FIB-4
Fibrosis
non-invasive
viral hepatitis
Journal
Hepatology forum
ISSN: 2757-7392
Titre abrégé: Hepatol Forum
Pays: Turkey
ID NLM: 9918351171306676
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
21
09
2020
accepted:
30
10
2020
entrez:
5
7
2022
pubmed:
8
1
2021
medline:
8
1
2021
Statut:
epublish
Résumé
This study was designed to predict the fibrosis stage with a clinical scoring system that may reduce the need for liver biopsy. The study cohort included the treatment of 430 chronic hepatitis B (CHB) and 170 chronic hepatitis C (CHC) of naive patients. The patients were divided into two groups as mild to moderate and severe fibrosis. After an index obtained in the study cohort, the index was tested in a validation cohort and compared with the FIB-4 Index. The AUC of CHC index was found of 0.89 the sensitivity of 0.91 the specificity of 0.74, the positive predictive value (PPV) of 0.54 and the negative predictive value (NPV) of 0.96. The FIB-4 Index was applied to the CHC study cohort and the ATA Index Hepatitis C was found to be superior in terms of AUC (0.89-0.82), sensitivity (0.91-0.76) and NPV (0.96-0.86). The AUC of CHB Index was determined of 0.92, the sensitivity of 0.90, the specificity of 0.84, the PPV of 0.53 and the NPV of 0.98. Compared to the FIB-4 Index in CHB study cohort, the ATA Index Hepatitis B was predominant in terms of AUC (0.92-0.88), sensitivity (0.90-0.75), NPV (0.98-0.94) and PPV (0.53-0.49). ATA Indexes can predict the non-existence of severe fibrosis with an accuracy similar to FIB-4 Index and may reduce the need for liver biopsy.
Sections du résumé
Background and Aim
UNASSIGNED
This study was designed to predict the fibrosis stage with a clinical scoring system that may reduce the need for liver biopsy.
Materials and Methods
UNASSIGNED
The study cohort included the treatment of 430 chronic hepatitis B (CHB) and 170 chronic hepatitis C (CHC) of naive patients. The patients were divided into two groups as mild to moderate and severe fibrosis. After an index obtained in the study cohort, the index was tested in a validation cohort and compared with the FIB-4 Index.
Results
UNASSIGNED
The AUC of CHC index was found of 0.89 the sensitivity of 0.91 the specificity of 0.74, the positive predictive value (PPV) of 0.54 and the negative predictive value (NPV) of 0.96. The FIB-4 Index was applied to the CHC study cohort and the ATA Index Hepatitis C was found to be superior in terms of AUC (0.89-0.82), sensitivity (0.91-0.76) and NPV (0.96-0.86). The AUC of CHB Index was determined of 0.92, the sensitivity of 0.90, the specificity of 0.84, the PPV of 0.53 and the NPV of 0.98. Compared to the FIB-4 Index in CHB study cohort, the ATA Index Hepatitis B was predominant in terms of AUC (0.92-0.88), sensitivity (0.90-0.75), NPV (0.98-0.94) and PPV (0.53-0.49).
Conclusion
UNASSIGNED
ATA Indexes can predict the non-existence of severe fibrosis with an accuracy similar to FIB-4 Index and may reduce the need for liver biopsy.
Identifiants
pubmed: 35782888
doi: 10.14744/hf.2020.2020.0027
pii: hf-2-12
pmc: PMC9138929
doi:
Types de publication
Journal Article
Langues
eng
Pagination
12-19Informations de copyright
© Copyright 2021 by Hepatology Forum - Available online at www.hepatologyforum.org.
Déclaration de conflit d'intérêts
Conflict of Interest: The authors have no conflict of interest to declare.
Références
Gastroenterology. 1988 Sep;95(3):734-9
pubmed: 3135226
Hepatology. 2008 Jan;47(1):332-42
pubmed: 18161879
Liver Int. 2017 Jan;37(1):121-131
pubmed: 26991726
Am J Gastroenterol. 2001 Nov;96(11):3142-6
pubmed: 11721762
Lab Hematol. 2010 Sep;16(3):28-31
pubmed: 20858586
Am J Gastroenterol. 2007 Nov;102(11):2589-600
pubmed: 17850410
J Viral Hepat. 2014 Dec;21(12):930-7
pubmed: 24472062
Hepatology. 1999 Dec;30(6):1529-30
pubmed: 10610352
Med Mal Infect. 2019 Nov;49(8):607-615
pubmed: 30871816
Hepatology. 2003 Dec;38(6):1449-57
pubmed: 14647056
Intervirology. 2007;50(6):408-11
pubmed: 18185013
Hepatology. 2002 Oct;36(4 Pt 1):986-92
pubmed: 12297848
Clinics (Sao Paulo). 2017 Oct;72(9):516-525
pubmed: 29069254
Aliment Pharmacol Ther. 2010 May;31(10):1085-94
pubmed: 20175770
N Engl J Med. 2001 Feb 15;344(7):495-500
pubmed: 11172192
Hepatology. 2005 Jun;41(6):1376-82
pubmed: 15915455
PLoS One. 2018 Jun 28;13(6):e0199760
pubmed: 29953518
Hepatology. 2015 Jan;61(1):292-302
pubmed: 25132233
Ann Med. 2012 Dec;44(8):805-16
pubmed: 22413913
Hepatology. 2007 Jul;46(1):32-6
pubmed: 17567829
PLoS One. 2014 Aug 28;9(8):e105728
pubmed: 25165830
Liver Int. 2011 Jan;31 Suppl 1:13-7
pubmed: 21205132
J Viral Hepat. 1997 May;4(3):199-208
pubmed: 9181529
Liver Int. 2010 Apr;30(4):546-53
pubmed: 20074094
N Engl J Med. 2004 Jul 29;351(5):438-50
pubmed: 15282351
J Microbiol Immunol Infect. 2020 Aug;53(4):542-549
pubmed: 31831303
Gastroenterol Clin North Am. 2015 Dec;44(4):717-34
pubmed: 26600216
Am J Gastroenterol. 1997 Aug;92(8):1302-4
pubmed: 9260794
Front Immunol. 2018 Nov 30;9:2795
pubmed: 30555477
Ann Gastroenterol. 2019 Sep-Oct;32(5):498-503
pubmed: 31474797
Hepatology. 2003 Aug;38(2):518-26
pubmed: 12883497
Clin Mol Hepatol. 2013 Jun;19(2):156-64
pubmed: 23837140